Murat Akova

About Murat Akova

Murat Akova, With an exceptional h-index of 65 and a recent h-index of 50 (since 2020), a distinguished researcher at Hacettepe Üniversitesi, specializes in the field of Immunocompromised host, febrile neutropenia, antimicrobial resistance.

His recent articles reflect a diverse array of research interests and contributions to the field:

Pseudomonas aeruginosa Bloodstream Infections Presenting with Septic Shock in Neutropenic Cancer Patients: Impact of Empirical Antibiotic Therapy

The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections

Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA)

Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients

Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM

Epidemiology and risk factors of 28-day mortality of hospital-acquired bloodstream infection in Turkish intensive care units: a prospective observational cohort study

Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)

VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe

Murat Akova Information

University

Position

___

Citations(all)

23923

Citations(since 2020)

14073

Cited By

14848

hIndex(all)

65

hIndex(since 2020)

50

i10Index(all)

160

i10Index(since 2020)

122

Email

University Profile Page

Google Scholar

Murat Akova Skills & Research Interests

Immunocompromised host

febrile neutropenia

antimicrobial resistance

Top articles of Murat Akova

Pseudomonas aeruginosa Bloodstream Infections Presenting with Septic Shock in Neutropenic Cancer Patients: Impact of Empirical Antibiotic Therapy

Microorganisms

2024/3/30

Murat Akova
Murat Akova

H-Index: 47

Rafael Araos
Rafael Araos

H-Index: 9

The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections

Intensive Care Medicine

2024/3/18

Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA)

Clinical Microbiology and Infection

2024/2/1

Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients

2024/1/1

Murat Akova
Murat Akova

H-Index: 47

Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM

Intensive Care Medicine

2024/4

Epidemiology and risk factors of 28-day mortality of hospital-acquired bloodstream infection in Turkish intensive care units: a prospective observational cohort study

Journal of Antimicrobial Chemotherapy

2023/7

VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe

Vaccine

2023/6/13

Risk factors for Gram-negative bacterial infection of cardiovascular implantable electronic devices: Multicentre observational study (CarDINe Study)

International journal of antimicrobial agents

2023/3/1

Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study

Intensive Care Medicine

2023/2/10

Immunogenicity and reactogenicity of a first booster with NT162b2or full-dose mRNA-1273: a randomised VACCELERATE trial in adults≥ 75 years (EU-COVAT-1)

2023/6/2

Duration of antibiotic treatment and timing of oral switching for bloodstream infections: a survey on the practices of infectious diseases and intensive care physicians

International Journal of Antimicrobial Agents

2023/6/1

Nick Daneman
Nick Daneman

H-Index: 32

Murat Akova
Murat Akova

H-Index: 47

“Good” News from IDCM and Thanks to All Who Contributed

Infectious Diseases & Clinical Microbiology

2023/12

Murat Akova
Murat Akova

H-Index: 47

2746. Assessment of in vitro synergy between Piperacillin-Tazobactam-Meropenem and Imipenem-Meropenem against OXA-48 Producing Klebsiella pneumoniae Using Time-Kill Assays

Open Forum Infectious Diseases

2023/12

Murat Akova
Murat Akova

H-Index: 47

Hacettepe health cohort (HU-CoVaCS): study design, baseline characteristics and the first 3-month-follow up of COVID-19 vaccinated students.

2023/5/30

The challenges of vaccine trial participation among underserved and hard-to-reach communities: an internal expert consultation of the VACCELERATE Consortium

Vaccines

2023/11/29

Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCELERATE Toolkit

JMIR public health and surveillance

2023/4/3

Q Fever Endocarditis-Associated Immune Complex-Mediated Proliferative Glomerulonephritis: Fourth Case from Türkiye

Mikrobiyoloji bulteni

2023/4

Rashad Ismayilov
Rashad Ismayilov

H-Index: 0

Murat Akova
Murat Akova

H-Index: 47

See List of Professors in Murat Akova University(Hacettepe Üniversitesi)